Arbutus Biopharma Corp.

As of June 27, 2025, Arbutus Biopharma Corp. is in a bearish trend with moderate strength, indicated by bearish signals from moving averages and Bollinger Bands, while mixed signals from MACD and mildly bearish readings from KST and OBV reinforce the negative sentiment.

As of June 10, 2025, the market trend is neutral with mixed signals: weekly indicators show mild bullishness while monthly indicators lean bearish, resulting in uncertainty and a lack of strong directional conviction.

As of March 2022, the management team of Arbutus Biopharma Corp. includes Dr. Frank Torti (Independent Chairman), Mr. William Collier (President and CEO), and six independent directors: Mr. Daniel Burgess, Dr. Andrew Cheng, Mr. Richard Henriques, Dr. Keith Manchester, and Mr. James Meyers.

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing a cure for chronic hepatitis B virus (HBV) infection. It has a market cap of approximately $660.77 million and reported net sales of $2 million with a net loss of $25 million in March 2025.

As of Jun 18, Arbutus Biopharma Corp. has a market capitalization of 660.77 million and reported net sales of 6.40 million with a net loss of 76.58 million over the last four quarters.